4D Molecular Therapeutics (FDMT) to Release Earnings on Friday

4D Molecular Therapeutics (NASDAQ:FDMT) is projected to post its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect 4D Molecular Therapeutics to post earnings of ($0.53) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

4D Molecular Therapeutics Stock Up 4.0%

Shares of NASDAQ FDMT opened at $10.07 on Wednesday. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $12.34. The stock has a market cap of $575.35 million, a price-to-earnings ratio of -2.69 and a beta of 3.01. The company’s fifty day moving average is $8.42 and its 200-day moving average is $8.85.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Chardan Capital reissued a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, December 18th. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Leerink Partners reaffirmed an “outperform” rating and set a $17.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Morgan Stanley upgraded shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research note on Friday, November 7th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 7th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $33.25.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Invesco Ltd. boosted its position in shares of 4D Molecular Therapeutics by 21.0% during the 4th quarter. Invesco Ltd. now owns 153,142 shares of the company’s stock worth $1,149,000 after acquiring an additional 26,563 shares in the last quarter. XTX Topco Ltd grew its stake in shares of 4D Molecular Therapeutics by 62.6% in the fourth quarter. XTX Topco Ltd now owns 65,022 shares of the company’s stock worth $488,000 after purchasing an additional 25,039 shares during the last quarter. Virtus Investment Advisers LLC acquired a new stake in shares of 4D Molecular Therapeutics in the fourth quarter valued at about $184,000. Susquehanna Portfolio Strategies LLC acquired a new stake in 4D Molecular Therapeutics during the 4th quarter valued at approximately $77,000. Finally, Tudor Investment Corp ET AL increased its position in shares of 4D Molecular Therapeutics by 23.5% during the fourth quarter. Tudor Investment Corp ET AL now owns 31,815 shares of the company’s stock worth $239,000 after buying an additional 6,048 shares during the period. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.